Motley Fool: Is Tilray Finally a Buy?

Canada’s top pot producers have all seen their valuations shoot higher this year — that is, except Tilray (NASDAQ:TLRY). Over the first five months of the year, Tilray’s market cap has slipped by an unsightly 25%. Worse still, the company’s…

Advertisements

Motley Fool: Why Marijuana Stocks Tilray, Cronos, and New Age Beverages Fell 10% to 19% in March

What happened Shares of cannabis companies Tilray (NASDAQ:TLRY), Cronos Group (NASDAQ:CRON), and New Age Beverages (NASDAQ:NBEV) dropped 19.4%, 14.8%, and 10.4%, respectively, in March, according to data from S&P Global Market Intelligence. For context, the S&P 500 rose 1.9% last month. Those stocks have…

Motley Fool: 3 Reasons Legal Weed Sales Aren't Getting Any Higher in Canada

According to Health Canada, licensed businesses sold 7,115 kilograms of dried flower in January. That was 3.7% less than in December, which hardly looks like a Canadian sales explosion that will help Aurora Cannabis (NYSE:ACB) or Cronos Group (NASDAQ:CRON) make ends meet before…

Motley Fool: Will Cannabis Producers Ditch Greenhouses for Bioreactors?

Investors cheered as brewing companies made moves into the nascent and increasingly deregulated cannabis industry in 2018. Canopy Growth (NYSE:CGC) won a $4 billion investment from beer giant Constellation Brands. Cronos Group (NASDAQ:CRON) linked up with Anheuser-Busch InBev to research…

Motley Fool: At What Price Is Cronos Group Worth Buying?

Marijuana stocks can seemingly do no wrong lately, and it’s not hard to see why. Since October, we’ve seen Canada legalize recreational marijuana, had a handful of U.S. states approve medical or recreational weed during midterm elections in November, witnessed…